Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scivision BiotechTPE:1786 -2.10%77 EV-to-EBIT is 14.29 as of Aug. 25, 2026, which is 46% below its 10-year median of 26.43. GuruFocus rates TPE:1786 with a GF Score™ of 77/100 and a GF Value™ of NT$101.22 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 476 Medical Devices & Instruments companies, Scivision Biotech ranks better than 63.24% on this metric.
The historical rank and industry rank for Scivision Biotech's EV-to-EBIT or its related term are showing as below:
TPE:1786'
s EV-to-EBIT Range Over the Past 10 Years
Min: -104.96 Med: 26.43 Max: 166.19
Current: 14.28
During the past 13 years, the highest EV-to-EBIT of Scivision Biotech was 166.19. The lowest was -104.96. And the median was 26.43.
TPE:1786's EV-to-EBIT is ranked better than 63.24% of 476
companies
in the Medical Devices & Instruments industry
Industry Median: 19
vs TPE:1786: 14.28
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Scivision Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$3,509.3 Mil.
Scivision Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$219.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scivision Biotech EV-to-EBIT Related Terms
Scivision Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Scivision Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1786 vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Scivision Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scivision Biotech EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Scivision Biotech's EV-to-EBIT falls into.
Scivision Biotech's current Enterprise Value is NT$3,130.9 Mil.
Scivision Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$219.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scivision Biotech (TPE:1786) has a EV-to-EBIT of 14.29 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scivision Biotech and its competitors. This is 46% below median its historical median of 26.43. According to the industry distribution chart, Scivision Biotech ranks #175 out of 476 companies in the Medical Devices & Instruments industry, placing it in the top 36.8%.
Is Scivision Biotech's EV-to-EBIT too high?
Scivision Biotech's current EV-to-EBIT of 14.29 is 46% below median its 10-year median of 26.43. The Medical Devices & Instruments industry median EV-to-EBIT is 19.00. Scivision Biotech's value of 14.29 is 24.8% below this industry median. Based on the distribution chart, Scivision Biotech ranks #175 out of 476 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Scivision Biotech has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Scivision Biotech ranks #175 out of 476 companies for EV-to-EBIT. This puts Scivision Biotech in the upper half of its industry. The industry median EV-to-EBIT is 19.00. Scivision Biotech's value of 14.29 is 24.8% below this benchmark. While the company's 10-year median is 26.43 vs. the industry median of 19.00, Scivision Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.00, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scivision Biotech's current EV-to-EBIT of 14.29 is 24.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scivision Biotech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scivision Biotech's current EV-to-EBIT is 14.29, which is 46% below median its own 10-year median of 26.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$101.22, compared to a current price of NT$48.85 — trading 51.7% below its estimated fair value. The current EV-to-EBIT is 14.29, which is 46% below median its 10-year median of 26.43 and 24.8% below the Medical Devices & Instruments industry median of 19.00. Scivision Biotech's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current EV-to-EBIT is 14.29 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scivision Biotech (TPE:1786) Overvalued in 2026?
Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued.
The current stock price of NT$48.85 is trading 51.7% below its estimated GF Value™ of NT$101.22.
GuruFocus considers Scivision Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1786:
EV-to-EBIT: 14.29 (46% below median its 10-year median of 26.43)
GF Value™: NT$101.22 vs. price of NT$48.85 (51.7% below fair value)
Industry Position: 24.8% below the Medical Devices & Instruments median (#175 of 476)
No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
77GF Score
Get the complete analysis for TPE:1786
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1786 has been successfully added to your 
